IMR Press / CEOG / Volume 45 / Issue 5 / DOI: 10.12891/ceog4566.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Intravenous Immunoglobulin (IVIg) for unexplained infertility: a case series
Show Less
1 Department of Immunology, Montreal General Hospital, McGill University, Montreal, Canada
2 McGill University, Montreal, Canada
3 Trio Fertility, Toronto, ON, Canada
4 Department of Medicine and Obstetrics, University of Toronto, Toronto, Canada
5 Reproductive Centre, McGill University, Montreal, Canada
6 Department of Obstetrics and Gynecology, University of Montreal, Montreal, Canada
7 Department of Reproductive Medicine, Ovo Clinic, Montreal, Canada
Clin. Exp. Obstet. Gynecol. 2018, 45(5), 699–701;
Published: 10 October 2018

Intravenous Immunoglobulin (IVIg) is a potential treatment for immune mediated reproductive failure (IMRF), but its role in infertility treatments remains controversial. There is evidence that administering IVIg before conception improves pregnancy outcomes. In the present cohort, 13/15 (86%) patients had a live birth after receiving pre-conceptual IVIg at immunomodulatory doses. No serious maternal or fetal side effects directly attributable to IVIg were reported. The present results support the need for a randomized controlled trial (RCT) with this protocol.
Maternal-fetal medicine
Back to top